St. Jude warning letter
This article was originally published in The Gray Sheet
Executive Summary
Puerto Rico AngioSeal femoral closure device manufacturing facility draws FDA warning letter citing quality system deficiencies detected in a fall 2004 inspection. "We take a warning letter with the utmost seriousness and priority. The warning letter arose from observations of an inspection of one of our plants last year. We responded both to those observations and to the warning letter with energetic corrective actions to address observed deficiencies at a root-cause level to ensure that they will never happen again," CEO Dan Starks remarked during St. Jude's April 21 earnings call. "We're in the process of further follow-up to close the loop with FDA." The letter has no impact on patients or a material impact on the company, he stated...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.